Noile-Immune to receive an up front & technology transfer fee, ~145.6M upon achievement of development or sales milestones & is also eligible to receive royalties upon the successful launch of product using PRIME technology
Chugai gets the rights to use PRIME technology to develop PRIME CAR-T cells & also obtains the rights to develop, manufacture & commercialize PRIME CAR-T cell products for certain targets
The collaboration focuses to make CAR-T cell therapy accessible to patients with solid tumors using PRIME & drug discovery technology. The preclinical studies showed that the PRIME technology increases the expression of IL-7 and CCL19 & boosts CAR-T & patients’ own immune cells’ proliferation & migration into solid tumors
Ref: Chugai | Image: Chugai
